UCG / Contributor / Getty Images Moderna shares surged Tuesday after Canadian regulators approved the biotech firm’s updated COVID-19 vaccine. Moderna's Spikevax KP.2 targets the KP.2 variant of ...

UPDATE on Sept. 17 at 8:49 a.m.: Casa Bonita reservations sell out on first day Since Casa Bonita reopened post-pandemic in 2023, it’s technically been in a soft opening phase – or “beta ...

Moderna’s shares climbed in the first half of the year, as it scored victories with a product approval and solid clinical trial results. This week the biotech surprised investors with some ...

Expanding its portfolio into oncology and rare diseases, positions Moderna to deliver ten product approvals within the next three years. The analyst notes the COVID-19 vaccine maker pushed its ...

TORONTO - Health Canada has authorized Moderna’s updated COVID-19 vaccine that protects against currently circulating variants of the virus. The mRNA vaccine, called Spikevax, has been ...

Moderna Therapeutics (NASDAQ: MRNA) was once the darling of the healthcare space for investors. The company emerged as one of the biggest names of the COVID-19 pandemic with its vaccine.

As of 1:12 PM EDT. Market Open. Moderna stock tumbled after the company issued a light 2025 sales outlook and cut its 2027 R&D budget. Is MRNA stock a sell? These biotech stocks have what it takes ...

ACCESSWIRE • 9 days ago EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-COV-2 Variant JN.

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non-small cell lung cancer ...